Prevalence of hemochromatosis gene (HFE) mutations in Greek patients with myelodysplastic syndromes

Acta Haematologica

Volumn 110, Issue 1, 2003, Pages 53-54

  Speletas, Matthaios ^a,d   Kioumi, Anna ^a   Mandala, Eudokia ^b   Katodritou, Eirini ^a   Papaioannou, Georgia ^a   Ritis, Konstantinos ^c   Korantzis, Ioannis ^a  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT;

ACUTE LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENZYME METABOLISM; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GREECE; HEMOCHROMATOSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LETTER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; REFRACTORY ANEMIA; STATISTICAL SIGNIFICANCE;

EID: 0141453415     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072419     Document Type: Letter

References (10)

1. Varkonyi J, Tarkovacs G, Karadi I, Andrikovics H, Varga F, Varga F, Demeter J, Tordai A: High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: The Budapest study on 50 patients. Acta Haematol 2003;109:64-67.
2. Fenaux P: Myelodysplastic syndromes. Hematol Cell Ther 1996,38:381-391.
3. Sanz GF, Sanz MA, Vallespi T: Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther 1997;39:277-294.
4. Feder JN, Gnirke A, Thomas W, et al: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
5. Hanson EH, Imperatore G, Burke W: HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154:193-206.
6. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D: Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 2000;26:163-168.
7. Brandhagen DJ, Fairbanks VF, Baldus WP, Smith CI, Kruckeberg KE, Schaid DJ, Thibodeau SN: Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol 2000;95:2910-2914.
8. Fargion S, Sampietro M, Cappellini MD: Thalassemias and their interactions with hemochromatosis; in Barton JC, Edwards CQ (eds): Hemochromatosis, Genetics, pathophysiology, diagnosis and treatment. Cambridge, Cambridge University Press, 2000, pp 435-441.
9. Bonkovsky HL, Lambrecht RW: Hemochromatosis, iron overload, and porphyria cutanea tarda; in Barton JC, Edwards CQ (eds): Hemochromatosis, Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press, 2000, pp 453-465.
10. Papazoglou D, Exiara T, Speletas M, Panagopoulos D, Maltezos E: Prevalence of hemochromatosis gene (HFE) mutations in Greece. Acta Haematol 2003;109:137-140.